MARK D KOCHENDERFER MD NPI 1396720454

NPI Details

Mark D Kochenderfer, MD is a hematology and oncology internal medicine in Roanoke, VA with 27 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Mark D Kochenderfer, MD NPI is 1396720454. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE
Graduation Year:1999

The provider's business location address is:

2013 JEFFERSON ST SW
ROANOKE, VA
ZIP 24014-419
Phone: (540) 982-0237
Fax: (540) 982-0103

The NPI 1396720454 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Vitamin d-3 level (HCPCS:82306)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Uric acid level, blood (HCPCS:84550)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Nephelometry, test method using light (HCPCS:83883)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Unclassified drugs (HCPCS:J3490)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Injection of drug or substance into vein (HCPCS:96374)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Thyroxine (thyroid chemical), total (HCPCS:84436)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Thyroid hormone, t3 measurement, total (HCPCS:84480)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Drawing of blood for a medical problem (HCPCS:99195)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Declotting of central venous tube (HCPCS:36593)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)

The enumeration date for this NPI number is 12/13/2005 and was last updated on 2/5/2013.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.